Uso dos inibidores seletivos da COX-2 na odontologia
Use of the COX-2 specific inhibitor in dentistry
Garcia Júnior, I.R.; Gaujac, C.; Gealh, W.C.; Magro Filho, O.; Hochuli Vieira, E.
Rev. odontol. UNESP, vol.34, n4, p.167-171, 2005
Resumo
Os analgésicos e os antiinflamatórios não esteroidais (AINES) estão entre os fármacos mais utilizados pela população. O uso desses medicamentos de forma crônica e aguda provoca alguns efeitos indesejáveis, como distúrbios gastrintestinais, lesões cutâneas, efeitos renais adversos e outros efeitos colaterais. Assim, as indústrias farmacêuticas passaram a desenvolver agentes analgésicos e antiinflamatórios que apresentem seletividade pela inibição da COX-2, os conhecidos coxibs, a fim de que se consiga efetividade clínica dos AINES com reduzidos riscos de efeitos gastrintestinais e outros colaterais, porém essas drogas vêm apresentando alguns outros efeitos adversos como alterações cardíacas o que limitaria o seu uso, demonstrando que não se justifica, portanto, o uso dos coxibs no exercício regular da odontologia, a não ser naqueles pacientes com história médica comprovada de distúrbio gastrintestinal.
Palavras-chave
Odontologia, antiinflamatórios, efeitos adversos.
Abstract
The non steroids anti inflammatory and analgesic medicines are among the most used medicines by population. The use of these medicines in a chronic and acute way promotes some undesirable effects such as gastro intestinal disturbs, skin lesions, adverse kidney effects and other side effects. So the pharmaceutical industries started developing analgesic and anti inflammatory agents presenting selectivity for the COX-2 inhibition, the so called coxibs, in order to achieve the clinical effectiveness with reduced risks of gastro intestinal effects and other side effects. But these drugs have presented some other adverse effects such as cardiac alterations which may limit their use demonstrating that the coxib use on the regular basis in dentistry is not justified with the exception of patients with medical history of confirmed gastrointestinal disturbs.
Keywords
Dentistry, anti-inflammatory agents, adverse effects
References
1. Rang HP, Dale MM, Ritter JM. Farmacologia. Rio de Janeiro: Editora Guanabara Koogan; 2001.
2. MERCK announces voluntary worldwide withdrawal of Vioxx; 2004 [citado em 2004 out 17]. Disponível em: http://www.vioxx.com/rofecoxib/vioxx/consumer/index. jsp.
3. PFIZER aviso [citado em 2005 abr 15]. Disponível em http://www.pfizer.com.br/comunicado.asp.
4. FDA.com information portal, 2005 [citado em 2005 abr 16]. Disponível em: http://www.fda.gov/cder/drug/infopage/ celebrex/celebrex-ptsk.htm.
5. Lichetenstein DR, Wolf MM. COX-2 selective NSAIDs: new and improved? J Am Med Assoc. 2000; 284: 1297- 9.
6. Agrawal NGB, Porras AG, Matthews CZ, Woolf EJ, Miller JL, Mukhopadhyay S, et al. Dose proportionality of oral Etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in health volunteers. J Clin Pharmacol. 2001; 41: 1106-10.
7. Galli G, Panzetta G. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol. 2002; 15: 480-8.
8. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. J Am Med Assoc. 2000; 284: 1247-55.
9. Agrawal NGB, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ, et al. Single and multiple dose pharmacokinetics of Etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol. 2003; 43: 268-76.
10. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet. 2004; 364: 665-74.
11. Day R. Another selective COX-2 inhibitor: more question than answers? J Rheumatol. 29: 1581-2.
12. Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol. 1997; 24(49): 20-4.
13. Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase- 2-specific inhibitor Rofecoxib in post dental surgery pain: a randomized, controlled trial. Clin Ther. 1999; 21: 943-53.
14. Desjardins PJ, Shu VS, Recker DP, Verburg KM, Woolf CJ. A single preoperative oral dose of Valdecoxib, a new cyclooxygenase-2 specific inhibitor; relieves post-oral surgery or burnionectomy pain. Anesthesiology. 2002; 97: 565-73.
15. Reuben SS, Connelly NR. Postoperative analgesic effects of Celecoxib or Rofecoxib after spinal fusion surgery. Anesth Analg. 2000; 91: 1221-5.
16. Tang J, LI S, White PF, Chen X, Wender RH, Quon R, et al. Effect of Parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology. 2002; 96: 1305-9.
17. Daniels SE, Grossman EH, Kuss ME, Talwalker S, Hubbard RC. A double-blind, randomized comparison of intramuscularly and intravenously administered Parecoxib Sodium versus Ketorolac and placebo in a post oral surgery pain model. Clin Ther. 2001; 23: 1018-30.
18. Harris RCJ. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol. 2002; 89(suppl): 10D-17D.
19. Eras J, Perazella MA. NSAIDs and the kidney revisited: are selective cyclooxygenase-2 inhibitors safe? Am J Medic Scienc. 321: 181-90.
20. Zhao SZ, Reinolds MW, Lefkowith J, Whelton A, Arellano FM. A comparison of renal-related adverse drug reactions between Rofecoxib and Celecoxib, based on the World Health Organization/Uppsala monitoring Centre Safety Database. Clin Ther. 2001; 23: 1479-91.
21. Harley C, Wagner S. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clin Ther. 2003; 139-149.
22. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, et al. Comparison of thromboembolic events in patients treated with Celecoxib, a cyclooxygenase- 2 specific inhibitor, versus Ibuprofen or Diclofenac. Am J Cardiol. 2002; 89: 425-30.
23. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FWA, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004 364: 375-84.
24. Kömhoff M, Gröne HJ, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997; 272: F460-468.
25. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos- Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343(21): 1520-8.
26. Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs. 2003; 63(1):33-45.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email